In vivo and ex vivo evaluation of L-type calcium channel blockers on acid β-glucosidase in Gaucher disease mouse models

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Sun, Ying ^a   Liou, Benjamin ^a   Quinn, Brian ^a   Ran, Huimin ^a   Xu, You Hai ^a   Grabowski, Gregory A ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLUCOSIDASE; DILTIAZEM; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; VERAPAMIL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; ENZYME LOCALIZATION; EX VIVO STUDY; FIBROBLAST; GAUCHER DISEASE; IN VIVO STUDY; MOUSE; NONHUMAN; POINT MUTATION; PROTEIN FOLDING; PROTEIN TRANSPORT; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; GENETICS; HOMOZYGOTE; METABOLISM; MUTATION; SKIN; TRANSGENIC MOUSE;

MUS;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; DILTIAZEM; DISEASE MODELS, ANIMAL; FIBROBLASTS; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HOMOZYGOTE; MICE; MICE, TRANSGENIC; MODELS, BIOLOGICAL; MUTATION; SKIN; VERAPAMIL;

EID: 70350234537     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007320     Document Type: Article

References (31)

1. Beutler E, Grabowski GA (2001) Gaucher Disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. eighth ed. New York: McGraw-Hill. pp 3635-3668.
2. Grabowski GA, Kolodny EH, Weinreb NJ, Rosenbloom BE, Prakash-Cheng A, et al. (2006) Gaucher disease: Phenotypic and genetic variation. Chapter 146.1. In: Scriver CR, Sly WS, Beaudet A, Valle D, Childs B, eds. The Metabolic and Molecular Bases of Inherited Diseases. New York: McGraw-Hill.
3. Tsuji A, Omura K, Suzuki Y (1988) Intracellular transport of acid alpha-glucosidase in human fibroblasts: evidence for involvement of phosphomannosyl receptor-independent system. J Biochem (Tokyo) 104: 276-278.
4. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160: 2835-2843.
5. Eyal N, Wilder S, Horowitz M (1990) Prevalent and rare mutations among Gaucher patients. Gene 96: 277-283.
6. Pasmanik-Chor M, Laadan S, Elroy-Stein O, Zimran A, Abrahamov A, et al. (1996) The glucocerebrosidase D409H mutation in Gaucher disease. Biochem Mol Med 59: 125-133.
7. Theophilus B, Latham T, Grabowski GA, Smith FI (1989) Gaucher disease: molecular heterogeneity and phenotype-genotype correlations. Am J Hum Genet 45: 212-225.
8. Xu YH, Quinn B, Witte D, Grabowski GA (2003) Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am J Pathol 163: 2093-2101.
9. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, et al. (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113: 112-119.
10. Weinreb NJ, Barranger JA, Charrow J, Grabowski GA, Mankin HJ, et al. (2005) Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol 80: 223-229.
11. Butters TD, Dwek RA, Platt FM (2005) Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology 15: 43R-52R.
12. Mu TW, Fowler DM, Kelly JW (2008) Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis. PLoS Biol 6: e26. doi: 10.1371/ journal.pbio.0060026.
13. Lieberman RL, Wustman BA, Huertas P, Powe AC, Jr., Pine CW, et al. (2007) Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol 3: 101-107.
14. Rigat B, Mahuran D (2009) Diltiazem, a L-type Ca(2+) channel blocker, also acts as a pharmacological chaperone in Gaucher patient cells. Mol Genet Metab 96: 225-232.
15. Zinchuk V, Zinchuk O, Okada T (2007) Quantitative colocalization analysis of multicolor confocal immunofluorescence microscopy images: pushing pixels to explore biological phenomena. Acta Histochem Cytochem 40: 101-111.
16. Nunia V, Goyal PK (2007) Protective effect of diltiazem (a calcium channel blocker) against cadmium-induced toxicity in mice. J Environ Pathol Toxicol Oncol 26: 185-193.
17. Luszczki JJ, Trojnar MK, Trojnar MP, Kimber-Trojnar Z, Szostakiewicz B, et al. (2007) Effects of three calcium channel antagonists (amlodipine, diltiazem and verapamil) on the protective action of lamotrigine in the mouse maximal electroshock-induced seizure model. Pharmacol Rep 59: 672-682.
18. Flynn JT, Pasko DA (2000) Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 15: 302-316.
19. Sun Y, Qi X, Grabowski GA (2003) Saposin C is required for normal resistance of acid beta-glucosidase to proteolytic degradation. J Biol Chem 278: 31918-31923.
20. Zhang F, Li PL (2007) Reconstitution and characterization of a nicotinic acid adenine dinucleotide phosphate (NAADP)-sensitive Ca2+ release channel from liver lysosomes of rats. J Biol Chem 282: 25259-25269.
21. Naito K, Nagao T, Otsuka M, Harigaya S, Nakajima H (1986) Penetration into and elimination from the cerebrospinal fluid of diltiazem, a calcium antagonist, in anesthetized rabbits. Arzneimittelforschung 36: 25-28.
22. Westermann D, Knollmann BC, Steendijk P, Rutschow S, Riad A, et al. (2006) Diltiazem treatment prevents diastolic heart failure in mice with familial hypertrophic cardiomyopathy. Eur J Heart Fail 8: 115-121.
23. Biala G (2003) Calcium channel antagonists suppress nicotine-induced place preference and locomotor sensitization in rodents. Pol J Pharmacol 55: 327-335.
24. Sawkar AR, Cheng WC, Beutler E, Wong CH, Balch WE, et al. (2002) Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease. Proc Natl Acad Sci U S A 99: 15428-15433.
25. Steet RA, Chung S, Wustman B, Powe A, Do H, et al. (2006) The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci U S A 103: 13813-13818.
26. Kornhaber GJ, Tropak MB, Maegawa GH, Tuske SJ, Coales SJ, et al. (2008) Isofagomine induced stabilization of glucocerebrosidase. Chembiochem 9: 2643-2649.
27. Eder C (1998) Ion channels in microglia (brain macrophages). Am J Physiol 275: C327-342.
28. Liu Y, Suzuki K, Reed JD, Grinberg A, Westphal H, et al. (1998) Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure. Proc Natl Acad Sci U S A 95: 2503-2508.
29. Sinclair GB, Jevon G, Colobong KE, Randall DR, Choy FY, et al. (2007) Generation of a conditional knockout of murine glucocerebrosidase: utility for the study of Gaucher disease. Mol Genet Metab 90: 148-156.
30. Enquist IB, Lo Bianco C, Ooka A, Nilsson E, Mansson JE, et al. (2007) Murine models of acute neuronopathic Gaucher disease. Proc Natl Acad Sci U S A 104: 17483-17488.
31. Sun Y, Witte DP, Zamzow M, Ran H, Quinn B, et al. (2007) Combined saposin C and D deficiencies in mice lead to a neuronopathic phenotype, glucosylceramide and alpha-hydroxy ceramide accumulation, and altered prosaposin trafficking. Hum Mol Genet 16: 957-971.